ATXN1L (ataxin 1 like) functions as a chr16-binding transcriptional repressor that forms critical regulatory complexes with the transcriptional repressor CIC (Capicua). This ATXN1L-CIC complex serves as a key gatekeeper of cellular homeostasis by binding to promoter regions and preventing aberrant expression of inflammatory genes, including interferons and interferon-stimulated genes, under normal conditions 1. During viral infection, MAPK pathway activation leads to rapid degradation of the CIC-ATXN1L complex, allowing robust induction of antiviral responses 1. The complex also regulates extracellular matrix remodeling during development by repressing matrix metalloproteinase genes through control of ETV transcription factors 2. Loss of ATXN1L destabilizes CIC protein and leads to derepression of ETV4, causing developmental defects including lung alveolarization abnormalities and hydrocephalus 2. In cancer contexts, ATXN1L expression inversely correlates with resistance to MAPK pathway inhibitors, as loss of ATXN1L or CIC promotes cancer cell survival during treatment 3. Additionally, ATXN1L shows therapeutic potential in spinocerebellar ataxia type 1 (SCA1), where overexpression can improve motor phenotypes and normalize disease-associated gene expression changes 4. The protein demonstrates functional redundancy with ATXN1, particularly in brain development and transcriptional regulation 5.